Printer Friendly

Ireland : Medtronic Announces CE Mark and European Launch of the Euphora(TM) Semicompliant Coronary Balloon Catheter.

Medtronic plc today announced the launch of the Euphora(TM) Semicompliant Balloon Dilatation Catheter in countries that recognize the CE (Conformite Europeene) mark. The first patient case with the Euphora Semicompliant Balloon Catheter was recently performed by Richard Edwards, M.D., consultant cardiologist at the Freeman Hospital in Newcastle, United Kingdom. It is not available in the United States.

"After performing the first patient case with Euphora, it is the most deliverable balloon catheter I have used," said Dr. Edwards. "The exceptionally low crossing profile and pushability make it ideal for complex situations and workhorse lesions alike."

Pre-dilatation with a semicompliant balloon helps physicians determine lesion characteristics, stent selection and facilitates stent access to the lesions - a crucial step for patients with complex lesions.

The Euphora Semicompliant Balloon Catheter features several design advancements including:

Delivery system with PowerTrac(TM) technology to provide superior deliverability (compared to major competitors)i through tight lesions. The delivery system was first introduced with the Medtronic NC Euphora(TM) Noncompliant Balloon Dilatation Catheter last year and is also featured with the Medtronic Resolute Onyx(TM) drug-eluting stent. A[degrees]A[degrees]A[degrees]

Ultra-slim balloon material, a tapered proprietary inner shaft design and an optimized mini-wrap to reduce the wall thickness of the balloon and contribute to the extremely low crossing profile. Significantly improved insertion and retraction force to enhance navigation to lesion sites when using the Kissing Balloon Technique, a method for treating bifurcated lesions. Environmentally friendly packaging, a reduced box size that has a smaller footprint on congested shelves and improved product labeling for fast readability to improve efficiency in the cath lab. Enhanced crossability may create economic value to the cath labs through the use of a single balloon prepping a lesion, thus reducing the need for the "step up" technique which requires several balloons of different size to first cross the tight lesions and then gradually expand sizing before treating with a stent.

"The Euphora family of balloons is a giant leap forward in balloon technology and builds upon our successful multi-brand strategy, which includes offering premium products at premium prices to help meet different customer needs," said Jason Weidman, vice president and general manager of the Medtronic coronary business. "Along with the previously launched noncompliant version of Euphora, these products exemplify our continued commitment to expand our interventional portfolio with innovative and differentiated technologies that address the needs of cath lab professionals around the world."

2015 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Feb 17, 2015
Previous Article:Ireland,Spain,United Kingdom : AER LINGUS named STEPHEN KAVANAGH as its new CEO to succeed MUELLER.
Next Article:Ireland : Medtronic Receives Expanded Indications of the VERTEX Reconstruction System.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters